Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)-

Request For Quotation
Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)- Suppliers list
Company Name: Shanghai Beckham Medical Technology Co., Ltd  
Tel: 13816613772
Email: huahero21@sina.com
Company Name: Tianjin Kailiqi Biotechnology Co., Ltd.  
Tel: 15076683720
Email: klq@cw-bio.com
Company Name: TargetMol Chemicals Inc.  
Tel: 15002134094
Email: marketing@targetmol.cn
Company Name: TargetMol Chemicals Inc.  
Tel: 13564774135
Email: marketing@targetmol.com

Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)- manufacturers

  • HDAC-IN-45
  • HDAC-IN-45 pictures
  • $1980.00
  • 2026-04-21
  • CAS:2421122-61-2
  • Purity:
  • Supply Ability: 10g
Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)- Basic information
Product Name:Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)-
Synonyms:Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)-;HDAC-IN-45
CAS:2421122-61-2
MF:C25H20ClFN8O
MW:502.93
EINECS:
Product Categories:
Mol File:2421122-61-2.mol
Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)- Structure
Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)- Chemical Properties
density 1.52±0.1 g/cm3(Predicted)
pka13.08±0.70(Predicted)
Safety Information
MSDS Information
Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)- Usage And Synthesis
UsesHDAC-IN-45 (Compound 14) is a small molecule HDAC inhibitor and has anticancer activity, also can forms a hydrogen bond with residue Y303. HDAC-IN-45 (Compound 14) has substantial inhibitory effects towards HDAC1, 2 and 3 isoforms with IC50 values of 0.108, 0.585 and 0.563 μM respectively[1].
in vivo

HDAC-IN-45 (Compound 14) (25 mg/kg or 50mg/kg; i.p.; every day) exhibits a potent antitumor efficacy in human MDA-MB-231 breast cancer xenograft mouse model[1].

Animal Model:Human MDA-MB-231 breast cancer xenograft mouse model[1]
Dosage:25 mg/kg or 50mg/kg
Administration:25 mg/kg or 50mg/kg; i.p.; every day.
Result:Exhibited a potent antitumor efficacy.
IC 50HDAC1: 0.108 μM (IC50); HDAC2: 0.585 μM (IC50); HDAC3: 0.563 μM μM (IC50); HDAC6: ﹥10 μM (IC50); HDAC8: 6.81 μM (IC50)
References[1] Kunal Nepali, et al. Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors. Eur J Med Chem. 2020 Jun 15;196:112291. DOI:10.1016/j.ejmech.2020.112291
Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)- Preparation Products And Raw materials
Tag:Benzamide, 4-[[2-amino-6-[(3-chloro-4-fluorophenyl)amino]-9H-purin-9-yl]methyl]-N-(2-aminophenyl)-(2421122-61-2) Related Product Information
Carbamazepine [4-[(Hydroxyamino)carbonyl]phenyl]carbamic acid [6-[(diethylamino)methyl]-2-naphthalenyl]methyl ester N-[2-Methyl-2-(2-phenyloxazol-4-yl)propyl]-3-[5-(trifluoroMethyl)-1,2,4-oxadiazol-3-yl]benzaMide Entinostat (1S,4Z,7S,10S,11E,20R)-4-ethylidene-7,20-dipropan-2-yl-9-oxa-15,16-dit hia-3,6,18,21-tetrazabicyclo[8.7.6]tricos-11-ene-2,5,8,19,22-pentone Tubacin